Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the antiStaphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA.
Introduction
Staphylococcus aureus, a gram-positive bacterium, is one of the leading causes of hospitaland community-acquired infections in developed countries. 1 It is estimated that S. aureus is commensally found on nasal passages, skin and mucous membranes of 20 -30% of the human population. 2, 3 S. aureus can cause infection of the bloodstream, lower respiratory antibiotics, S. aureus has also developed resistance to several other classes of antibiotics, including aminoglycosides, macrolides, lincosamides, chloramphenicol, sulfonamides, streptomycin and tetracycline. 4, 7 The capability of S. aureus to resist multiple antibiotics has rendered its treatment difficult, leading to a higher mortality in patients. Thus, development of new antibacterial agents against S. aureus, especially strains resistant to multiple antibiotics, has become an urgent public health issue.
Previously, we reported that the cyclooxygenase-2 (COX-2) inhibitor celecoxib and its derivatives exhibited unique antimicrobial activities against various pathogenic bacteria in vitro, including Salmonella and Francisella. [8] [9] [10] This anti-bacterial effect, however, was not noted with rofecoxib, a more potent COX-2 inhibitor, suggesting the dissociation of these two pharmacological activities. In addition, celecoxib was recently reported to inhibit multidrug resistance in pathogenic bacteria, 11 and has been used to develop a new class of efflux pump inhibitors. 12 In this study, we further demonstrated the unique ability of celecoxib to directly suppress, though with modest potency, the growth of S. aureus, S. epidermidis and MRSA. As celecoxib has been shown to suppress cancer cell proliferation, in part, by competing ATP binding of certain signaling kinases, such as phosphoinositidedependent kinase-1 (PDK-1) 13 and cyclin-dependent kinases (CDKs), 14 and endoplasmic reticulum Ca 2+ -ATPases, 15 we hypothesize that celecoxib mediates the bacterial killing by blocking ATP-dependent enzymes or transporters that are crucial to cell survival. Pursuant to this premise, we conducted a screening of an in-house celecoxib-based focused compound library, followed by structural optimization, to identify novel agents that exhibit high anti-MRSA potencies without acute cytotoxicity against human cells.
Results and discussion
In this study, we screened a celecoxib-based focused compound library to identify candidate anti-Staphylococcus agents for lead optimization ( Figure 1A ). Previously, during the course of our lead optimization of celecoxib to develop novel PDK-1 inhibitors, 13, 16 we generated a series of derivatives with varying degrees of antiproliferative potency against cancer cells. Of these derivatives, we chose 40 representative celecoxib derivatives for screening against S. aureus and S. epidermidis (1 -40; Fig. 2 ), which are noteworthy because they represent the most common causes of medical device-associated infections. 17 This screening netted compound 36 as the lead anti-Staphylococcus agent, followed by compound 9. Further structural modifications of 36 by substituting the phenanthrene ring with various aromatic structures yielded 41 -47, of which compound 46 was identified as the optimal agent. General procedures for the synthesis of compounds 1 -47 are depicted in Fig. 1B. 
Suppressive effect of celecoxib on the growth of Staphylococcus bacteria
Pursuant to our previous finding that celecoxib inhibited the proliferation of Salmonella and Francisella directly in culture medium, [8] [9] [10] we examined its suppressive effect on the growth of S. aureus (ATCC 29213), S. epidermidis (ATCC 35984), and two different strains of MRSA (ATCC 33592 and SCCmec V T ). Celecoxib exhibited a clear, though modest, activity against these staphylococcal bacteria with the minimum inhibitory concentrations (MIC) of 32 μg/mL for S. aureus and both strains of MRSA, and 16 μg/mL for S. epidermidis. Exposure of S. aureus to celecoxib at the MIC of 32 μg/mL after 24 h resulted in a 6-log decrease in CFU relative to that of control (data not shown). In light of the absence of COX-2-like gene in bacteria, 11 this finding suggests that celecoxib's antiStaphylococcus activity was dissociated from it effects on COX-2.
Identification of novel anti-Staphylococcus agents
The dissociation of these two pharmacological activities (antibacterial versus anti-COX-2) provided a molecular basis for the pharmacological exploitation of celecoxib to develop novel anti-Staphylococcus agents. As the target for celecoxib's anti-Staphylococcus activity remained unknown, we used an in-house, celecoxib-based focused compound library consisting of 40 derivatives with modifications to the terminal aromatic group (R) and polar side chain (Fig. 2) , which were screened for growth inhibitory activities against S. aureus (ATCC 29213) and S. epidermidis (ATCC 35984). Of these derivatives, compounds 1 -8 and 10 of the carboxamide series, 12 -15 of the sulfonamide series, 16 -20 of the amine series, 21, 22, 32, and 37 -40 did not exhibit appreciable activity at 64 μg/mL or improved activity relative to celecoxib (data not shown). However, other derivatives exhibited multifold increases in anti-Staphylococcus potency (Table 1) , providing a proof-of-concept of our premise that celecoxib could be structurally modified to enhance its anti-Staphylococcus activity. Among these more active derivatives, compound 36, followed by compound 9, represented the lead agents with MIC values of ≤ 2 μg/mL against both S. aureus and S. epidermidis.
As celecoxib is cytotoxic to cancer cells, [18] [19] [20] the growth inhibitory activities of celecoxib and selected derivatives were assessed in HT-29 human colon adenocarcinoma cells after 24-h exposure. As shown in Table 1 , most of the active anti-Staphylococcus compounds examined suppressed the viability of HT-29 cells with high potency (low IC 50 values), resulting in low selectivity ratios, defined as IC 50 /MIC against S. aureus. It is noteworthy that compounds 9 and 36, the lead anti-Staphylococcus derivatives, showed lower cytotoxic activity against HT-29 cells relative to the other compounds resulting in the highest selectivity ratios (6 and 12, respectively), indicating a better selectivity in suppressing the growth of Staphylococcus versus HT-29 cells.
The above findings underscore the translational potential of compounds 9 and 36 to develop potent anti-Staphylococcus agents. Based on these results, we hypothesized that there existed interplay between the terminal aromatic system and the hydrophilic side chain to mediate the anti-Staphylococcus activity through the interactions with target protein(s). In light of the modestly improved antibacterial activity of compound 36 relative to compound 9, we used the former compound as a scaffold for structural modifications by replacing the 2-phenanthrenyl ring with various aromatic systems, generating compounds 41 -47 (Fig.  1A) . These derivatives were assessed for their antibacterial activities against S. aureus (ATCC 29213) and S. epidermidis (ATCC 35984), which revealed some degree of flexibility in altering the size of the aromatic ring. For example, the phenanthrene ring could be replaced by biphenyl or substituted biphenyls (42 -44) without compromising the antiStaphylococcus activity. Of particular interest is the substitution with an anthracen-9-yl moiety (compound 46), which gave rise to a twofold increase in the anti-Staphylococcus potency with MIC of 0.5 μg/mL (Table 2) . Moreover, compound 46 exhibited lower antiproliferative potency against HT-29 cancer cells (IC 50 , 20 μg/mL), providing a selectivity ratio of 40 relative to that of 12 for compound 36. It is noteworthy that compound 46 represents a hybrid of compounds 9 and 36, underlying a subtle structure-activity relationship in interacting with the bacterial target.
Antibacterial spectra of compounds 9, 36, and 41 -46 against different Staphylococcus species
As different strains/species of Staphylococcus might respond differently to the antibacterial effects of these novel agents, we further expanded our investigation to include a panel of representative Staphylococcus pathogens, consisting of different strains of S. aureus, S. epidermidis and MRSA, as well as S. haemolyticus, S. hominis, S. intermedius, S. saprophyticus, and S. lugdunesis.
As shown in Table 3 , the inhibitory potencies of these test agents against the three strains of MRSA, including the multidrug-resistant community-associated MRSA that carries the novel staphylococcal chromosome cassette mec (SCCmec) subtype V, 21 T were consistent with those of S. aureus and S. epidermidis. Among these derivatives, compound 46
represented the optimal anti-MRSA agent with MIC of 0.5 μg/mL, followed by compounds 36 and 42 -44, all of which exhibited an MIC value of 1 μg/mL. Moreover, as these MRSA strains have been reported to resist different classes of antibiotics, 7, 21, 22 this finding suggests that a novel antibacterial target is involved in the mechanism of action of these agents.
Other non-Staphylococcus aureus species examined, with the exception of S. intermedius, showed a lesser degree of susceptibility to compounds 36 and 46, with MIC around 2 μg/ mL. In contrast, the potency of compound 9 remained relatively unchanged across different Staphylococcus species.
Compounds 36 and 46 are bactericidal against S. aureus
An antibacterial agent is defined as bactericidal when it exhibits the distinctive endpoint of causing a 99.9% reduction in bacterial inoculum within a 24-h period of exposure. 23 Otherwise, it is considered bacteriostatic. To category these novel agents, represented by compounds 9, 36, and 46, in this regard, their time-killing kinetics were assessed in S. aureus ATCC 29213 over a 24-h treatment period as compared to the known bactericidal and bacteriostatic agents ampicillin and chloramphenicol, respectively. Overnight-grown bacteria were inoculated in cation-adjusted Muller Hinton broth (CAMHB) at a concentration of 5 × 10 5 CFU/mL followed by exposure to individual compounds at 2-to 8-fold their respective MIC values. As shown in Fig. 3 , compounds 9, 36, and 46 caused timedependent killing of S. aureus, achieving reductions in CFU of 99.14%, 99.91%, and 99.99% respectively, after 24-h exposure to 8 times the MIC. In comparison to ampicillin and chloramphenicol, the bacterial killing effect of compounds 36 and 46 were charactristic of bactericidal, while the antibacterial effect of compound 9 was not sufficient to be defined as bactericidal.
Intraperitoneal administration of compound 46 improves the survival of MRSAinfected C57BL/6 mice
To further evaluate the therapeutic potential of compounds 36 and 46 against MRSA, inbred C57BL/6 mice were intraperitoneally injected with a lethal dose (7 × 10 7 CFU) of MRSA (ATCC 33592), followed by a single, intraperitoneal administration of vehicle control or compound 36 or 46 at 30 mg/kg at 1 h post-infection (N = 5 for each group). Mice treated with vehicle or compound 36 rapidly developed signs of severe infection that included weight loss of over 20%, significant decrease in body temperature, and lethargy. Survival time for these mice was no more than 2 days (Fig. 4A) . Among the five mice that received a single dose of compound 46 at 30 mg/kg, three mice died during the first day post-infection ( Fig. 4A) . However, two of the compound 46-treated mice survived for at least 7 days postinfection, exhibiting decreases of body weight at 1 day post-infection that returned to preinfection levels after 3 -6 days post-infection (Fig. 4B) . It is noteworthy that, other than body weight loss, no other signs of illness were observed in these two mice. Together, these findings provided a proof-of-concept that compound 46 exhibited anti-Staphylococcus activity in vivo.
Discussion
Although hospitals have fought MRSA infections since the late 1960s, the past two decades have witnessed severe community-associated MRSA cases affecting healthy, young individuals with no link to the healthcare system. 24 To date, S. aureus has developed various mechanisms to evade the inhibitory effect of almost all classes of antibiotics, as well as the third-line agent vancomycin. 25, 26 Consequently, MRSA represents an impending public health crisis, and there is an urgent need to develop new anti-MRSA agents with distinct modes of antibacterial action to overcome the multi-drug resistance. Here, we report the pharmacological exploitation of the suppressive effect of the COX-2 inhibitor celecoxib on the growth of Staphylococcus bacteria to develop a novel class of anti-MRSA agents with high potency.
In this study, we tested three different strains of MRSA, all of which exhibit resistance to multiple antibiotics, including oxacillin, clindamycin, sulfonamides, erythromycin, tetracycline, cotrimoxazole, gentamicin, chloramphenicol, and streptomycin. 7, 21, 22 Despite this multi-drug resistant phenotype, all of the MRSA strains were as sensitive to the inhibitory effects of compounds 46, 36, and 9 as the methicillin-sensitive S. aureus strains,
with MIC values in the range of 0.5 to 2 μg/mL. This lack of cross-resistance suggests that the mode of action of these compounds is different from those of existing antibiotics. To shed light onto the potential antibacterial target of these compounds, we are currently identifying bacterial proteins with homology to mammalian targets of celecoxib using the published proteome of S. aureus and S. epidermidis at the National Center of Biotechnology Information (http://www.ncbi.nlm.nih.gov/). 27 Previously, we demonstrated that celecoxib mediated the antiproliferative effect in cancer cells by targeting a number of non-COX enzymes, including certain signaling kinases, such as PDK-1 13 and CDKs, 14 and endoplasmic reticulum Ca 2+ -ATPases. 15 Through BLASTP analysis, we have identified a number of bacterial proteins of S. aureus and S. epidermidis with some degree of homology to PDK-1 and endoplasmic reticulum calcium ATPases, including a serine/threonine kinase (NP_764450), the copper transporter ATPase copA, potassium transporter ATPase subunit B, and cadmium transporting ATPase. Evaluation of the involvement of these putative targets in the anti-Staphylococcus effects of compounds 9, 36, and 46, in conjunction with genomic analysis of drug-resistant mutants, is currently underway. From a translational perspective, understanding the mode of action of these novel agents will foster new strategies for the treatment of staphylococcal infections.
Conclusion
The high potency of compounds 36 and 46 in eradicating MRSA in vitro justifies continued preclinical development of these compounds in animal models as potential therapeutic agents against infection with MRSA. In addition, identification of the molecular target by which these agents kill Staphylococcus bacteria will help design more potent anti-MRSA agents for clinical use.
Material and methods

Chemistry general methods
Celecoxib was prepared from Celebrex® capsules (Amerisource Health, Malvern, PA) by solvent extraction followed by recrystallizaion from a mixture of ethyl acetate and hexane.
Unless otherwise indicated, all anhydrous solvents were commercially obtained and stored in Sure-seal bottles under nitrogen. All other reagents and solvents were purchased as the highest grade available and used without further purification. Flash column chromatography was performed with silica gel (Sorbent Technologies, 230-400 mesh). Nuclear magnetic resonance spectra ( 1 H NMR) were acquired on a Bruker DPX 300 model spectrometer. Chemical shifts (δ) were reported in parts per million (ppm) relative to the TMS peak. Coupling constants (J) were reported in Hertz throughout. Electrospray ionization mass spectrometry analyses were performed with a Micromass Q-Tof II high-resolution electrospray mass spectrometer. The purity of all tested compounds was determined to be greater than 95% by elemental analyses, which were performed by Atlantic Microlab, Inc. (Norcross, GA) and were reported within 0.4% of calculated values. All synthesized compounds were soluble in organic solvents, including DMSO.
General procedure of carboxamide series (9) and the aminosulfonamide series (36 and 41 -47)
The sulfonamide series compounds 11 -15, the amine series compounds 16 -20, and the amino acid series compounds 22 -35 and 38 -40 were synthesized as previously described. 16, 28 Syntheses of the active compounds of the carboxamide series (i.e., 9) and the aminosulfonamide series (i.e., 36 and 41 -47) are illustrated by the syntheses of compounds 9 and 36, respectively, as examples.
Step a. To a suspension of ethyl trifluoroacetate (850 mg, 6 mmol, 1.2 eq.) and NaH (150 mg, 6.25 mmol, 1.25 eq.) in anhydrous THF, individual ketone substrates (5 mmol, 1 eq.) in anhydrous THF were slowly added at 25 ° C. The resulting mixture was stirred for 5 h, concentrated, diluted with ethyl acetate, washed, in tandem, with water, 1N HCl and brine. The organic phase was dried over sodium sulfate, filtered and concentrated. The residue was purified by flash column chromatography (EtOAc-hexane, 1:4) to afford pure 1,3-diketone in fair to good yields.
Step b. A mixture of the 1,3-diketone from step a (3 mmol, 1 eq.), individual hydrazaine substrates (3.75 mmol, 1.25 eq.), and concentrated HCl (0.4 mL, 1.5 eq.) in ethyl alcohol was refluxed until the reaction completed (monitored with TLC; EtOAc-hexane, 3:7). The resulting mixture was concentrated, diluted with ethyl acetate, and washed with water and brine. The organic phase was dried over sodium sulfate, filtered and concentrated. The residue was purified by flash column chromatography (EtOAc-hexane, 3:7) to yield pure pyrazole ring derivatives.
Step c. To a solution of 4-(5-anthracen-9-yl-3-trifluoromethyl-pyrazol-1-yl)-benzonitrile generated from step b (206 mg, 0.5 mmol, 1 eq.) in DMSO (1 mL) were added Na 2 CO 3 (106 mg, 1 mmol, 2 eq.) and H 2 O 2 (30%, 0.2 mL, 3 eq.) at 0 °C. The reaction mixture was stirred at 20 °C for 3 h, and water (3 mL) was added. The white precipitate was filtered, washed with water, and dried over sodium sulfate, and filtered to afford compound 9 (177 mg) as off-white crystal in 82% yield.
Step d. A reaction mixture of various 5-aryl-1-(4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole derivatives (3 mmol, 1 eq.), generated from step b, platinum oxide (PtO 2 , 23 mg, 0.1 mmol, 0.03 eq.) in EtOH was stirred overnight under H 2 atmosphere, filtered, and washed with ethyl acetate. The combined filtrate was concentrated and the residue was purified with flash column chromatography (CH 2 Cl 2 -NH 4 OH, 99.9:0.1) to give the corresponding amines with quantitative yields. -9-yl-3-trifluoromethyl-pyrazol-1-yl) 
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aminosulfonamide (36)-Chlorosulfonyl isocyanate (142 mg, 1 mmol, 1 eq.) was added dropwise to an ice-cold solution of t-BuOH (74 mg, 1 mmol, 1 eq.) in CH 2 Cl 2 , which was then added to a mixture of 4-(5-phenanthren-2-yl-3-trifluoromethyl-pyrazol-1-yl)-phenylamine (403 mg, 1 mmol, 1 eq.), generated from step d, and triethylamine (152 mg, 1.5 mmol, 1.5 eq.) in CH 2 Cl 2 . The reaction mixture was stirred at 25 °C for 1 h, and concentrated. The residue was treated with 20% trifluoroacetic acid in CH 2 Cl 2 for 3 h, washed with 10% NaHCO 3 , dried over sodium sulfate, and concentrated. The residue was purified by flash column chromatograph (MeOH-CH2Cl2-NH4OH, 2:97.9:0.1) to give 36 (388 mg) as off-white solid in 78% yield. 1 N-{4-[5-(4′-Methylbiphenyl-4-yl)-3-tirfluoromethyl-pyrazol-1-yl] N-{4-[5-(4′-Bromobiphenyl-4-yl)-3-trifluoromethyl-pyrazol-1-yl] Naphthalen-2-yl-3-trifluoromethyl-pyrazol-1-yl) 
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Antibacterial assays
The MIC of each agent was determined following the guidelines for the broth microdilution method recommended by the Clinical and Laboratory Standards Institute. 29 Briefly, bacteria grown overnight on Luria Bertani (LB) agar plates were suspended in phosphate-buffered saline (PBS) to an O.D. of 1.0 at 600 nm, which was equivalent to 2 × 10 9 CFU/mL, and then diluted in CAMHB to a final concentration of 5 × 10 5 CFU/mL. The bacterial suspensions were exposed to the test agents and chloramphenicol at escalating doses, ranging from 0.25 to 64 μg/mL, in triplicate in 96-well plates, and the plates were incubated at 37°C for 24 h. The MIC of each agent was defined as the lowest concentration at which no growth of bacteria was observed. Stock solutions of the test agents were made in DMSO at 100 mg/mL, and diluted in culture medium to a final DMSO concentration of 0.1%.
Antiproliferative assay
The cytotoxicity of individual test agents in HT-29 human colon adenocarcinoma cells was evaluated by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay. Briefly, HT-29 cells were seeded into 96-well plates at 1 × 10 4 cells/well (with a minimum of 6 wells per test condition) in RPMI 1640 medium supplemented with 10% FBS and 10 μg/mL of gentamicin. After overnight incubation at 37°C under 5% CO 2 , the medium from each well was removed and replenished with fresh aliquots of the same medium containing various concentrations of test agents dissolved in DMSO (final concentration, 0.1%). Control cells were treated with DMSO alone at a concentration equal to that in drug-treated cells. After 24 h of drug exposure, the medium was removed and replaced by 100 μl of 0.5 mg/mL MTT in 10% FBS-containing medium, and the cells were incubated in the CO 2 incubator at 37°C for 2 h. Subsequently, medium was removed from each well, and the reduced MTT dye was dissolved with 100 μl of DMSO per well. Absorbance at 570 nm was measured with a plate reader. The 50% inhibitory concentration (IC 50 ) of each drug was determined from dose-response curves by using CalcuSyn software (Biosoft, Cambridge, United Kingdom).
Time-kill assay
To analyze the kinetics of bacterial cell killing, S. aureus ATCC 29213 cells at a density of 5 × 10 5 CFU/mL were treated with test agents at 2-, 4-, and 8-fold MICs in triplicate in 24-well plates. Bacterial survival in medium containing DMSO at a concentration equal to that used for drug-treated bacteria served as control. At different times after the start of drug exposure, a 100 μl aliquot of the bacterial suspension was taken from each well and serially diluted with PBS. The diluted samples were spread onto LB agar plates followed by incubation at 37°C for 16 h. The bacterial colonies on each plate were enumerated, and the number of viable bacteria in each well was expressed as CFU per milliliter.
In vivo studies
Female C57BL/6 mice (8 to 10 weeks of age) were purchased from the National Laboratory Animal Center (Taipei, Taiwan), and housed as groups under conditions of constant photoperiod (12 h light, 12 h dark) with ad libitum access to sterilized food and water in the Laboratory Animal Center, College of Medicine, National Taiwan University. All experimental procedures with these mice were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of the National Taiwan University. Overnight-grown methicillin-resistant Staphylococcus aureus (ATCC 33592) were diluted (1:100) in Luria Bertani broth and grown at 37°C to OD 600 =0.6, harvested by centrifugation, washed and resuspended in sterile PBS. Mice were infected by intraperitoneal administration of MRSA (7 × 10 7 organisms in 0.3 ml PBS; a 100% lethal dose) through a 1 ml syringe with 25 gauge needle. The same bacterial culture was plated onto LB agar to confirm the number of organisms inoculated. At 1 h post-infection, mice were assigned to treatment groups and then received a single treatment of vehicle (40% PEG-400, 10% 2-hydroxyl-β-dextran, 10% DMSO in normal saline), compound 36 or compound 46 by intraperitoneal injection. Observations of general health and measurements of body weight were recorded daily. The survival time of each mouse was recorded and was defined as the time in days from the start of the study to when mice were sacrificed upon exhibiting signs of significant morbidity, which included, though were not limited to, weight loss of 20% of initial body weight. Table 3 Antibacterial spectra of compounds 9, 36, and 41 -47 vis-à-vis ampicillin and chloramphenicol against a panel of 
